Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Baylor Breast Care Center GlaxoSmithKline |
---|---|
Information provided by: | Baylor Breast Care Center |
ClinicalTrials.gov Identifier: | NCT00548184 |
We think that lapatinib will help to shrink your tumor when given prior to the main or primary therapy for the kind of breast cancer you have been diagnosed with. When treatment is given before the main or primary therapy, it is called neoadjuvant therapy. We will compare lapatinib with lapatinib plus trastuzumab (herceptin) for 12 weeks. If your tumor is estrogen receptor positive (ER positive), estrogen deprivation will also be given to you.
Tumors that are ER positive have a lot of estrogen receptors found in them. This is also called "over expression" or amplification of estrogen receptors.
The most important information we will get from this study is to see the response to "neoadjuvant" (treatment given before the main treatment), lapatinib with trastuzumab (herceptin) in your tumor tissue sample.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: Lapatinib Drug: Trastuzumab Drug: Endocrine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients |
Estimated Enrollment: | 64 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | January 2020 |
Estimated Primary Completion Date: | January 2015 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Note: The presence of pathological involvement of axillary nodes will be assessed and agreed upon by two investigators.
Exclusion Criteria:
Contact: Anne C Pavlick, BS | 713-798-7770 | acpavlic@breastcenter.tmc.edu |
Contact: Brenda Reusser, BA | 713-798-1929 | breusser@breastcenter.tmc.edu |
United States, Alabama | |
UAB Cancer Center | Not yet recruiting |
Birmingham, Alabama, United States, 35294 | |
Contact: Pam Dixon 205-975-5387 PaPam.Dixon@ccc.uab.edu | |
Principal Investigator: Andres Forero, MD | |
United States, Illinois | |
The University of Chicago | Not yet recruiting |
Chicago, Illinois, United States, 60637 | |
Contact: Amanda Spratt, CCRP 773-834-4031 aspratt@medicine.bsd.uchicago.edu | |
Contact: Erin Mueller (773)702-0859 emueller@medicine.bsd.uchicago.edu | |
Principal Investigator: Rita Nanda, MD | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research | Not yet recruiting |
Baltimore, Maryland, United States, 21231-1000 | |
Contact: Stacie Jeter, CCRP 410-614-6138 sjeter1@jhmi.edu | |
Principal Investigator: Antonio C Wolf, MD | |
United States, Minnesota | |
Mayo Clinic Cancer Center | Not yet recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Rochelle Kozera 507-538-8267 kozera.rochelle@mayo.edu | |
Principal Investigator: James Ingle, MD | |
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center | Recruiting |
Nashville, Tennessee, United States, 37232-6868 | |
Contact: Kerek E Frierson 615-322-5092 kerek.frierson@vanderbilt.edu | |
Principal Investigator: Ingrid A Mayer, MD | |
United States, Texas | |
Baylor College of Medicine, Lester and Sue Smith Breast Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Anne Pavlick, BS 713-798-1999 acpavlic@bcm.tmc.edu | |
Principal Investigator: Jenny Chang, MD |
Principal Investigator: | Jenny C Chang, MD | Baylor Breast Center |
Responsible Party: | Baylor College of Medicine ( Jenny Chang ) |
Study ID Numbers: | H-20464 |
Study First Received: | October 19, 2007 |
Last Updated: | May 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00548184 History of Changes |
Health Authority: | United States: Food and Drug Administration |
primary breast cancers Locally advanced breast cancers |
Antibodies, Monoclonal Antibodies Skin Diseases Trastuzumab Breast Neoplasms |
Lapatinib Protein Kinase Inhibitors Breast Diseases Immunoglobulins |
Skin Diseases Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Breast Neoplasms Lapatinib Enzyme Inhibitors Protein Kinase Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Trastuzumab Breast Diseases |